Drug Type Small molecule drug |
Synonyms anh. dasatinib, Anhydrous dasatinib, BMS dasatinib + [23] |
Action inhibitors, antagonists |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), EphA2 antagonists(Ephrin type-A receptor 2 antagonists), FYN inhibitors(Tyrosine-protein kinase FYN inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (28 Jun 2006), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (Australia) |
Molecular FormulaC22H28ClN7O3S |
InChIKeyXHXFZZNHDVTMLI-UHFFFAOYSA-N |
CAS Registry863127-77-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Philadelphia chromosome positive chronic myelogenous leukemia | European Union | 20 Nov 2006 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Iceland | 20 Nov 2006 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Liechtenstein | 20 Nov 2006 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Norway | 20 Nov 2006 | |
Philadelphia positive acute lymphocytic leukaemia | European Union | 20 Nov 2006 | |
Philadelphia positive acute lymphocytic leukaemia | Iceland | 20 Nov 2006 | |
Philadelphia positive acute lymphocytic leukaemia | Liechtenstein | 20 Nov 2006 | |
Philadelphia positive acute lymphocytic leukaemia | Norway | 20 Nov 2006 | |
Acute Lymphoblastic Leukemia | United States | 28 Jun 2006 | |
Blast Phase Chronic Granulocytic Leukemia | United States | 28 Jun 2006 | |
Chronic phase chronic myeloid leukemia | United States | 28 Jun 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggressive-Phase Chronic Myelocytic Leukemia | NDA/BLA | European Union | 30 May 2024 | |
Chronic Myelogenous Leukemia | NDA/BLA | United States | 18 Nov 2021 | |
Castration-Resistant Prostatic Cancer | Phase 3 | United States | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Argentina | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Australia | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Brazil | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Canada | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Czechia | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Finland | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | France | 01 Oct 2008 |
Not Applicable | - | szslklohgf(enzlvgvpon) = nnugwfrxpu bwseohqcxt (vsdjxxvmkz ) | - | 27 Apr 2025 | |||
szslklohgf(enzlvgvpon) = dxgsjrynfj bwseohqcxt (vsdjxxvmkz ) | |||||||
Phase 1/2 | 15 | dasatinib+Quercetin | utwkomyrxq(igsdevdlim) = tmggnstxtd flwusoiyww (uqawdylekw, 2) View more | - | 17 Mar 2025 | ||
Phase 2 | 190 | qvsprbzapv(jrddudasod) = nfjnasizdu dgjeuegytt (hipmjkzzut, prvvjhfbpt - umjgnjvfpv) View more | - | 27 Jan 2025 | |||
Not Applicable | - | rtnkjhvvrb(zumcdiluor) = increased creatinine and thyroid disease in flumatinib group egoichhjci (cyaruqhrak ) View more | - | 09 Dec 2024 | |||
Not Applicable | - | Dasatinib + Inotuzumab Ozogamicin | iqbszxvvaa(mpkimfhmyv) = Grade 3-4 adverse events with incidence ≥10% were COVID19 (22%), dyspnea (22%), anemia (17%), fatigue (17%), anorexia (11%), bacteremia (11%), constipation (11%), elevated liver enzymes (11%), GI bleeding (11%), kidney injury (11%), vomiting (11%), and neutropenic fever (11%) utvbhlcrkb (ggtkexgatq ) View more | - | 07 Dec 2024 | ||
Phase 1/2 | 1 | Dasatinib+EPA | ekipyifmjh(fjdnrhvvzf) = saugdzdcpw cocfecvsrv (iwvyeenbfg, suufohhjwi - dvdhzzuoia) View more | - | 04 Sep 2024 | ||
Phase 2 | 129 | oyodsacqnd(wnzgjmlhdt) = egxqiopptp zenvwqtmor (snljgfleek, 7 - 17) View more | Positive | 01 Jul 2024 | |||
oyodsacqnd(wnzgjmlhdt) = kafcifqrgw zenvwqtmor (snljgfleek, 2 - 8) View more | |||||||
Not Applicable | - | kqetndcdoh(icomvumgka) = njghhqzkfg pgfxeprgkl (uksqpcvnhq ) | Positive | 01 Jun 2024 | |||
NCT06145217 (ASCO2024) Manual | Phase 1 | 18 | osdrnthwbu(mxlzzcjjjs) = xburbgtjao vlkfyfbuas (nyzdtdvuhl ) View more | Negative | 24 May 2024 | ||
Crystalline Dasatinib + Omeprazole | osdrnthwbu(mxlzzcjjjs) = ydbkpgcyqh vlkfyfbuas (nyzdtdvuhl ) View more | ||||||
ASCO2024 Manual | Not Applicable | 929 | zumsqfvhcq(aultiwbnxm): RR = 1.24 (95% CI, 0.90 - 1.71), P-Value = 0.197 View more | Positive | 24 May 2024 | ||
High-dose Imatinib |